Evaluation of 3‐ and 4‐Phenoxybenzamides as Selective Inhibitors of the Mono‐ADP‐Ribosyltransferase PARP10. Issue 10 (19th June 2021)

• Record Type: Journal Article
• Authors: Korn, Patricia; Classen, Arno; Murthy, Sudarshan; Guareschi, Riccardo; Maksimainen, Mirko M.; Lippok, Barbara E.; Galera‐Prat, Albert; Sowa, Sven T.; Voigt, Catharina; Rossetti, Giulia; Lehtiö, Lari; Bolm, Carsten; Lüscher, Bernhard
• Is Part Of: ChemistryOpen. Volume 10:Issue 10(2021)
• Page Start: 939
• Page End: 948
• Publication Date: 2021-06-19
• Subjects: ADP-ribosylation -- cell proliferation -- compound screening -- DNA repair -- molecular modeling; Chemistry -- Periodicals; 540; 540.5
• DOI: 10.1002/open.202100087
• Languages: English
• ISSNs: 2191-1363

Abstract

Abstract: Intracellular ADP‐ribosyltransferases catalyze mono‐ and poly‐ADP‐ribosylation and affect a broad range of biological processes. The mono‐ADP‐ribosyltransferase PARP10 is involved in signaling and DNA repair. Previous studies identified OUL35 as a selective, cell permeable inhibitor of PARP10. We have further explored the chemical space of OUL35 by synthesizing and investigating structurally related analogs. Key synthetic steps were metal‐catalyzed cross‐couplings and functional group modifications. We identified 4‐(4‐cyanophenoxy)benzamide and 3‐(4‐carbamoylphenoxy)benzamide as PARP10 inhibitors with distinct selectivities. Both compounds were cell permeable and interfered with PARP10 toxicity. Moreover, both revealed some inhibition of PARP2 but not PARP1, unlike clinically used PARP inhibitors, which typically inhibit both enzymes. Using crystallography and molecular modeling the binding of the compounds to different ADP‐ribosyltransferases was explored regarding selectivity. Together, these studies define additional compounds that interfere with PARP10 function and thus expand our repertoire of inhibitors to further optimize selectivity and potency. Abstract : ADP‐ribosyltransferases are involved in many different cellular processes, including DNA repair, signaling, and innate immunity. Inhibitors of PARP1/2 are in clinical use to treat several types of cancers. Here, we describe novel inhibitors of PARP10, which is deregulated in disease. We addressed the specificity of the inhibitors using structural and enzymatic studies, which will contribute to the further development of small molecule PARP inhibitors.